James D. Chalmers

37.7k total citations · 6 hit papers
483 papers, 14.4k citations indexed

About

James D. Chalmers is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Emergency Medical Services. According to data from OpenAlex, James D. Chalmers has authored 483 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 352 papers in Pulmonary and Respiratory Medicine, 164 papers in Epidemiology and 80 papers in Emergency Medical Services. Recurrent topics in James D. Chalmers's work include Cystic Fibrosis Research Advances (260 papers), Neonatal Respiratory Health Research (151 papers) and Tracheal and airway disorders (96 papers). James D. Chalmers is often cited by papers focused on Cystic Fibrosis Research Advances (260 papers), Neonatal Respiratory Health Research (151 papers) and Tracheal and airway disorders (96 papers). James D. Chalmers collaborates with scholars based in United Kingdom, Italy and United States. James D. Chalmers's co-authors include Adam T. Hill, Aran Singanayagam, Stefano Aliberti, Ahsan R. Akram, Simon Finch, Melissa J. McDonnell, Pieter Goeminne, Thomas C. Fardon, Francesco Blasi and Holly R. Keir and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

James D. Chalmers

442 papers receiving 14.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Bronchiectasis Severity Index. An International Derivation and Validation Study

2014 665 citations James D. Chalmers, Pieter Goeminne et al. American Journal of Respiratory and Critical Care Medicine profile →
Pneumonia

2021 411 citations Antoní Torres, Catia Cillóniz et al. Nature Reviews Disease Primers profile →
Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity

2018 269 citations Patrick A. Flume, James D. Chalmers et al. profile →
Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis

2017 247 citations James D. Chalmers, Guillermo Suárez-Cuartín et al. American Journal of Respiratory and Critical Care Medicine profile →
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

2020 207 citations James D. Chalmers, Charles Haworth et al. profile →
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

2025 26 citations James D. Chalmers, Pierre‐Régis Burgel et al. profile →

Peers

Countries citing papers authored by James D. Chalmers

Since Specialization

Citations

This map shows the geographic impact of James D. Chalmers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. Chalmers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. Chalmers more than expected).

Fields of papers citing papers by James D. Chalmers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. Chalmers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. Chalmers. The network helps show where James D. Chalmers may publish in the future.

Co-authorship network of co-authors of James D. Chalmers

This figure shows the co-authorship network connecting the top 25 collaborators of James D. Chalmers. A scholar is included among the top collaborators of James D. Chalmers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. Chalmers. James D. Chalmers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Study Design of a Phase III Study (AIRTIVITY®) of the Novel Cathepsin C (Dipeptidyl Peptidase 1) Inhibitor BI 1291583 in People With Bronchiectasis 2025 ·American Journal of Respiratory and Critical Care Medicine ·James D. Chalmers, Michal Shteinberg, Sanjay H. Chotirmall, (unknown), Patrick A. Flume, Raksha Jain, (unknown), Anne E. O’Donnell, Felix C. Ringshausen, (unknown), Jin‐Fu Xu, (unknown), (unknown), (unknown), Marcus Mall, Pamela J. McShane	1
2	Efficacy of Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis With vs Without Maintenance Use of Macrolides: An Analysis of the ASPEN Trial 2025 ·American Journal of Respiratory and Critical Care Medicine ·Charles Haworth, Pamela J. McShane, David Mauger, Mark L. Metersky, (unknown), Vivian H. Shih, Ariel Teper, (unknown), (unknown), Kevin C. Mange, James D. Chalmers	0
3	The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe COPD: a randomised trial (MUSIC) 2025 ·European Respiratory Journal ·Hollian Richardson, (unknown), Clare Clarke, Abirami Veluchamy, Petra Rauchhaus, Jennifer S. Pollock, (unknown), Diane Cassidy, Holly R. Keir, Simon Finch, (unknown), (unknown), Andrew Smith, Manish Patel, (unknown), Gourab Choudhury, Devesh Dhasmana, Rekha Chaudhuri, Philip Short, James D. Chalmers	0
4	ANNUALIZED EXACERBATION RATE IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS BY PRESPECIFIED SUBGROUPS IN THE PH3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ASPEN TRIAL 2024 ·CHEST Journal ·Mark L. Metersky, Pierre‐Régis Burgel, Charles L. Daley, Anthony De Soyza, Charles Haworth, David Mauger, Michael R. Loebinger, Timothy R. Aksamit, Naoki Hasegawa, Kozo Morimoto, Felix C. Ringshausen, Kevin C. Mange, Ariel Teper, (unknown), (unknown), Xiangmin Zhang, James D. Chalmers	2
5	Global genomic diversity of Pseudomonas aeruginosa in bronchiectasis 2024 ·Journal of Infection ·(unknown), (unknown), Kathleen A. Cagney, M. J. Shepherd, Elizabeth Grimsey, Tiwei Fu, (unknown), (unknown), (unknown), Dylan Z. Childs, Joanne L. Fothergill, James D. Chalmers, Michael A. Brockhurst, Steve Paterson	3
6	Accelerated elastin degradation by age-disease interaction: a common feature in age-related diseases 2024 ·PubMed ·(unknown), Anna Maria Choy, Chim C. Lang, Bruce E. Miller, Ruth Tal‐Singer, Charlotte E. Bolton, Neil C. Thomson, James D. Chalmers, Matthew J. Bown, David E. Newby, Faisel Khan, Jeffrey Huang	6
7	SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial 2024 ·ERJ Open Research ·Merete Long, (unknown), Yan Hui Giam, Thenmalar Vadiveloo, (unknown), Holly R. Keir, (unknown), (unknown), (unknown), Sarah K. Inglis, Chloe Hughes, (unknown), Marek Gierliński, (unknown), Graeme MacLennan, Albena T. Dinkova‐Kostova, James D. Chalmers	2
8	Changes in Blood Immune Cell Transcriptomes Associate With Disease Severity, Infection, and Inflammation in Bronchiectasis Patients: Data From the EMBARC-BRIDGE Study 2024 ·(unknown), Lídia Perea, (unknown), Jennifer S. Pollock, Chloe Hughes, Caroline S. Clarke, Michal Shteinberg, Stefano Aliberti, Charles Haworth, Sanjay H. Chotirmall, (unknown), Pieter Goeminne, Michael R. Loebinger, (unknown), Felix C. Ringshausen, Rosa Faner, Oriol Sibila, Amelia Shoemark, James D. Chalmers	0
9	P094 A Phase II study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 in patients with cystic fibrosis bronchiectasis (the Clairafly™ study) 2023 ·Journal of Cystic Fibrosis ·Marcus Mall, (unknown), Jane C. Davies, Scott H. Donaldson, (unknown), (unknown), (unknown), Raksha Jain, B. K. Rubin, James D. Chalmers	5
10	Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease 2023 ·Frontiers in Immunology ·James D. Chalmers, Ralph Kettritz, Brice Korkmaz	27
11	The Economic Burden of Bronchiectasis 2023 ·CHEST Journal ·(unknown), Vikas Goyal, Sanjeewa Kularatna, Anne B. Chang, Nitin Kapur, James D. Chalmers, Pieter Goeminne, (unknown), Julie M. Marchant, Steven McPhail	23
12	Therapeutic Targeting of the Respiratory Microbiome 2022 ·American Journal of Respiratory and Critical Care Medicine ·Sanjay H. Chotirmall, Debby Bogaert, James D. Chalmers, Michael J. Cox, Philip M. Hansbro, Yvonne J. Huang, Philip L. Molyneaux, David N. O’Dwyer, Alexa A. Pragman, Geraint B. Rogers, Leopoldo N. Segal, Robert P. Dickson	41
13	Pneumonia breakdown → 2021 ·Nature Reviews Disease Primers ·Antoní Torres, Catia Cillóniz, Michael S. Niederman, Rosario Menéndez, James D. Chalmers, Richard G. Wunderink, Tom van der Poll	411
14	Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes 2021 ·PubMed ·David Price, Rupert Jones, Pascal Pfister, Hui Cao, Victoria Carter, Anu Kemppinen, Björn Holzhauer, Alan Kaplan, Allan Clark, David Halpin, Hilary Pinnock, James D. Chalmers, Job F. M. van Boven, Kai Michael Beeh, Κonstantinos Κostikas, Nicolás Roche, Omar S. Usmani, (unknown)	9
15	Assessment of Phenotype Microarray plates for rapid and high-throughput analysis of collateral sensitivity networks 2019 ·PLoS ONE ·(unknown), James D. Chalmers, (unknown), Thomas J. Finn, Wayne M. Patrick	6
16	Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients 2018 ·Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) ·Marcos I. Restrepo, (unknown), Luis Felipe Reyes, James D. Chalmers, Nilam J. Soni, Oriol Sibila, Paola Faverio, Catia Cillóniz, (unknown), Stefano Aliberti, (unknown)	12
17	Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD 2016 ·Respirology ·Ana Rodrigo‐Troyano, Guillermo Suárez-Cuartín, (unknown), (unknown), Diego Castillo, F Sánchez, Vicente Plaza, Marcos I. Restrepo, James D. Chalmers, Oriol Sibila	38
18	Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care-Associated Pneumonia: A UK Cohort Study 2011 ·Clinical Infectious Diseases ·James D. Chalmers, Joanne Taylor, Aran Singanayagam, G. B. Fleming, Ahsan R. Akram, P. Mandal, Gourab Choudhury, Adam T. Hill	185
19	Admission hypoglycaemia is associated with adverse outcome in community-acquired pneumonia 2009 ·European Respiratory Journal ·Aran Singanayagam, James D. Chalmers, Adam T. Hill	16
20	Lieser and misconceptions 2008 ·ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) ·James D. Chalmers	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact